 Mass High Tech | Zalicus drops Synavive RA drug after disappointing Ph IIb results The Pharma Letter US biotech firm Zalicus (Nasdaq: ZLCS) saw its shares plunge nearly 40% to $0.84 in afternoon trading Monday, after saying it would discontinue further development of its rheumatoid arthritis (RA) drug candidate Synavive (prednisolone/dipyramidamole). Zalicus slumps after ending Synavive development "Better Than Nothing" Doesn't Cut It for Zalicus Zalicus (ZLCS) To Discontinue Further Synavive Development In Rheumatoid ... |
